| Symbol | ALLR |
|---|---|
| Name | ALLARITY THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 123 E TARPON AVE, TARPON SPRINGS, Florida, 34689, United States |
| Telephone | +1 401 - 426-4664 |
| Fax | — |
| — | |
| Website | https://www.allarity.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001860657 |
| Description | Allarity Therapeutics Inc is a clinical-stage, precision medicine company. Additional info from NASDAQ: |
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Read moreAllarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Read moreAllarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Read more(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Provides Update on step for Allarity
Read moreAllarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Read more(90% Positive) ALLARITY THERAPEUTICS, INC. (ALLR) Announces Enrollment Update for observed Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Read moreAllarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026
Read more(99% Neutral) ALLARITY THERAPEUTICS, INC. (ALLR) Reports Q2 2026 Financial Results
Read moreAllarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05571969 | Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patie… | Phase1 | Advanced Solid Tumors | Terminated | 2023-03-08 | 2024-10-07 | ClinicalTrials.gov |
| NCT04796324 | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by … | Phase2 | Metastatic Breast Cancer | Terminated | 2021-03-01 | 2025-11-01 | ClinicalTrials.gov |
| NCT03878849 | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Ad… | Phase2 | Advanced Ovarian Cancer | Recruiting | 2019-04-15 | 2027-09-01 | ClinicalTrials.gov |
| NCT03877796 | Clinical Pre-screening Protocol for Ovarian Cancer | — | Ovarian Cancer | Recruiting | 2019-04-11 | 2027-12-01 | ClinicalTrials.gov |
| NCT03562832 | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-1… | Phase2 | Metastatic Breast Cancer | Completed | 2018-06-20 | 2024-08-01 | ClinicalTrials.gov |
| NCT03196947 | Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Mu… | Phase1 | Relapsed/Refractory Multiple Myeloma | Terminated | 2017-06-13 | 2020-01-16 | ClinicalTrials.gov |
| NCT01861496 | Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patient… | Phase1 | Phase 1: Advanced or Refractory Solid Tumours | Completed | 2013-04-01 | 2021-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Drug Response Predictor® (DRP) | Drug | Preclinical | Ovarian Cancer | RECRUITING | NCT03877796 |
| Drug Response Predictor® (DRP) | Drug | Preclinical | Ovarian Cancer | RECRUITING | NCT03877796 |
| 2X-121 + 500 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 + 400 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 + 300 mg dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 1000 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 800 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| 2X-121 600 mg | Other | Phase PHASE1 | Advanced Solid Tumors | TERMINATED | NCT05571969 |
| APO010 | Other | Phase PHASE1 | Relapsed/Refractory Multiple Myeloma | TERMINATED | NCT03196947 |
| LiPlaCis | Other | Phase PHASE1 | Phase 1: Advanced or Refractory Solid Tumours | COMPLETED | NCT01861496 |
| PARP inhibitor 2X-121 | Other | Phase PHASE2 | Metastatic Breast Cancer | COMPLETED | NCT03562832 |
| 2X-121 and dovitinib | Other | Phase PHASE1 | Advanced Solid Tumors | SUSPENDED | NCT05571969 |
| 2X-121 | Other | Phase PHASE2 | Advanced Ovarian Cancer | RECRUITING | NCT03878849 |
| Drug Response Predictor® (DRP) | Drug | Preclinical | Ovarian Cancer | RECRUITING | NCT03877796 |
| Ixabepilone Injection | Other | Phase PHASE2 | Metastatic Breast Cancer | TERMINATED | NCT04796324 |